Please login to the form below

Not currently logged in
Email:
Password:

Mylan hires Jacek Glinka as European head

He will join the firm from Poland’s Polpharma

Mylan Jacek GlinkaUS pharma company Mylan has named Jacek Glinka as president of its European business.

Glinka will join Mylan in December when he steps down from his role as CEO of Poland's Polpharma, which he headed up from 2003 to 2006 and then again from 2009 to the present.

During this time, he helped expand Polpharma from a small local biopharma to one that now stretches across Central and Eastern Europe and Asia. As a result of the expansion, including takeovers of firms in Poland and Kazakhstan, revenues doubled between 2011 and 2013 to reach more than $1bn.

In his role at Mylan, Glinka will oversee the company's growth plans in Europe and will report to chief operating officer Hal Korman.

“We believe Jacek's strong leadership, strategic thinking and operational discipline will build on the solid foundation and leadership team we already have in place, and maximise the many opportunities we see ahead for our European business,” said Mylan's CEO Heather Bresch.

Glinka added that he had been following Mylan for some time and he was confident that company could become a serious competitor in Europe.

“I look forward to leveraging my expertise, particularly in the exciting Central and Eastern European markets, to further expand Mylan's footprint,” he said.

21st October 2013

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Attigo (part of the Mednet Group)

Inclusion drives innovation. Attigo, a social enterprise, helps pharma and the socially conscious business shape the future by engaging with...

Latest intelligence

Enabling market access through outcomes-based pricing
Outcomes-based pricing is a potential solution to create a link between product price and real-world outcomes, while at the same time facilitating patient access to new and innovative medicines....
Five companies 20 for 2020
20 for 2020 – Five pharma companies to watch
As a new decade gets into gear, we take a look at five pharma companies that have a lot riding on 2020...
The growing clinical importance of patient-reported outcomes (PROs)
Traditionally, the success or otherwise of medical treatments has been assessed by mortality or clinical assessments of health. However, patient self-reports of health are increasingly seen as central to the...

Infographics